



**Written submission from
Becton, Dickinson and Company**

**Mémoire de
Becton, Dickinson and Company**

In the Matter of

À l'égard d'

Ontario Power Generation

Ontario Power Generation

Ontario Power Generation – Licence amendment application for the Darlington Nuclear Generating Station regarding the commercial production of Cobalt-60

Ontario Power Generation – Demande concernant la modification de son permis pour la centrale nucléaire de Darlington en vue de produire commercialement du Cobalt-60

Public Hearing – Hearing in writing based on written submissions

Audience publique – Audience fondée sur des mémoires

Spring 2024

Printemps 2024



BD
1 Becton Drive
Franklin Lakes, NJ 07417
Tel.: +1 201 847 6800
www.BD.com

February 12, 2024

Canadian Nuclear Safety Commission
280 Slater St
PO Box 1046 Stn B
Ottawa ON K1P 5S9

Re: Application from Ontario Power Generation for the amendment of its power reactor operating license seeking to authorize OPG to commercially produce cobalt-60 at the Darlington Nuclear Generating Station

Dear Canadian Nuclear Safety Commission,

On behalf of Becton, Dickinson and Company (BD), I would like to express BD's support for Ontario Power Generator's license amendment request regarding the commercial production of cobalt-60. BD is one of the largest global medical technology companies in the world and is **advancing the world of health™** by improving medical discovery, diagnostics, and the delivery of care.

Cobalt-60 is used as source material in the sterilization of single use medical devices by gamma irradiation, protecting patients from risk of infection. Single use medical devices include, but are not limited to; needles, syringes, IV sets, blood collection sets, diagnostic products, PPE, test media, and various laboratory products. Globally, it is estimated that 30-40% of medical devices are sterilized using gamma irradiation, which has been proven as a safe and reliable method of sterilization.

The demand for single use medical devices continues to grow at unprecedented rates. Increasing the supply of cobalt-60 is critical to ensure continued supply of sterile products to patients across Canada and throughout the world. Approval of commercial cobalt-60 production at the Darlington Nuclear Generating Station would be a great contribution to meeting the growing demand for sterile medical devices and ensuring the highest level of patient care.

Sincerely,

A handwritten signature in black ink, appearing to read 'T. Anderton', is written over a light blue horizontal line.

Travis Anderton
Vice President, Sterilization
Office: +1.801.565.2810
email: travis.anderton@bd.com